Skip to main content
. 2014 Nov 10;8:1555–1569. doi: 10.2147/PPA.S66966

Table S1.

Participants’ characteristics at baseline

Completers (n=40) Withdrawals (n=14) P
Sociodemographics
 Age, years 51 (15) 50 (17) 0.83
 Men, n (%) 14 (35) 7 (50) 0.32
 Cohabitation (yes), n (%) 24 (60) 6 (43) 0.27
 Employed (yes), n (%) 18 (45) 9 (65) 0.21
 Education level (≥12 years), n (%) 21 (52) 9 (64) 0.44
Clinical and functional profile
 Refill: β2LA + ICS or ICS alone, % 15 (38) 6 (33) 0.72
 Refill: combined β2LA + ICS, % 25 (62) 8 (57)
 Total dose of combined β2LA and/or ICS, mg 739 (461) 675 (618) 0.68
 Anti-leukotrienes, n (%) 11 (27) 1 (7) 0.15
 Anti-rhinitics, n (%) 13 (32) 6 (43) 0.53
 FEV1, L 2.0 (0.7) 2.2 (1.1) 0.51
 FEV1, % predicted 67 (15) 74 (39) 0.51
 FVC, L 2.4 (1.1) 2.7 (1.3) 0.53
 FVC, % predicted 67 (17) 77 (54) 0.47
 FEV1/FVC, % predicted 103 (17) 102 (18) 0.78
 Atopic, n (%) 33 (82) 10 (72) 0.45
 Current smoker (yes), n (%) 4 (10) 3 (21) 0.36
 BMI, kg · m−2 31 (8) 29 (6) 0.53
 Waist circumference, cm 95 (16) 95 (10) 0.98
 Asthma duration, years 25 (20) 21 (12) 0.44
 Bronchodilator use, # last week 6 (8) 12 (19) 0.25
 Bronchodilator use, # per puff 1.5 (0.5) 1.4 (0.5) 0.30
 ACT scores (5–25) 17 (4) 18 (3) 0.22
 ACQ scores (0–6) 1.9 (0.9) 2.0 (1.3) 0.61
 ASES total scores (1–5) 2.6 (0.1) 2.6 (0.2) 0.91
 Morisky scores (5–30) 22 (5) 22 (4) 0.93
 AQLQ scores (1–7)
  Total 4.9 (0.9) 4.9 (1.2) 0.94
  Activity limitations 4.5 (1.2) 4.6 (1.4) 0.75
  Symptoms 5.0 (0.9) 4.9 (1.2) 0.78
  Emotional function 5.4 (1.2) 5.5 (1.3) 0.77
  Exposure 4.7 (1.4) 4.7 (1.4) 0.96

Notes: Data are expressed as mean (SD) or n (%).

Abbreviations: MI, motivational interviewing; β2LA, long-acting beta2-agonists; ICS, inhaled corticosteroid; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; BMI, body mass index; AQLQ, asthma quality-of-life questionnaire; ACT, Asthma Control Test; ACQ, Asthma Control Questionnaire; ASES, Asthma Self-Efficacy Scale.